Patents by Inventor Jimena Bouzas-Rodriguez

Jimena Bouzas-Rodriguez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMA
    Publication number: 20140186364
    Abstract: The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 3, 2014
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE CLAUDE BERNARD LYON 1, ECOLE NORMALE SUPERIEURE DE LYON, CENTRE LEON BERARD
    Inventors: Patrick Etienne-Roger MEHLEN, Servane Marie-Séverine Tauszig-Delamasure, Céline Jacqueline-Andrée Delloye, Jimena Bouzas-Rodriguez
  • INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMA
    Publication number: 20110229485
    Abstract: The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain, or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells.
    Type: Application
    Filed: May 22, 2009
    Publication date: September 22, 2011
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTFIQUE (CNRS), CENTRE LEON BERARD, ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Patrick Etienne Roger Mehlen, Servane Marie-séverine Tauszig-Delamasure, Céline Jacqueline-Andrée Delloye, Jimena Bouzas-Rodriguez